1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial
    Meeting Abstract

    Motzer, R. J.; Porta, C.; Eto, M.; Hutson, T. E.; Rha, S. Y.; Merchan, J. R.; Winquist, E.; Gurney, H.; Grünwald, V.; George, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Evorpacept plus enfortumab vedotin in patients (Pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Phase 1a dose escalation results
    Meeting Abstract

    Funt, S. A.; Grivas, P.; Gao, X.; Vaena, D. A.; Zhang, T.; Milowsky, M. I.; Rao, M.; Liu, H.; Tipton, K.; An, G.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Intratumoral T-cell infiltration and response to nivolumab plus ipilimumab in patients with metastatic clear cell renal cell carcinoma from the CheckMate-214 trial
    Meeting Abstract

    Matar, S.; Jegede, O.; Denize, T.; Ghandour, F.; Laimon, Y. N.; El Ahmar, N.; Sheshdeh, A. B.; Savla, V.; Mohanna, R. A.; Catalano, P. J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Biomarker analysis of zanzalintinib in clear cell renal cell carcinoma from STELLAR-001
    Meeting Abstract

    Pal, S. K.; Medioni, J.; de Velasco, G.; Merchan, J. R.; Büchler, T.; Apolo, A. B.; Loriot, Y.; Wang, Z.; Jew, T.; Cao, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune)
    Meeting Abstract

    McKay, R. R.; Liu, L.; Pu, M.; Araneta, A.; Yuen, K. L.; Gomez, J.; Castano, N.; Ajmera, A.; Ye, H.; Pili, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQOL) results from PRESTO (AFT-19), a phase 3 randomized trial of intensification of androgen blockade in patients with high-risk biochemically relapsed castration sensitive prostate cancer
    Meeting Abstract

    Chen, R. C.; Mazza, G. L.; Fruth, B.; Xiao, H.; Picus, J.; Taplin, M. E.; Dorff, T. B.; Appleman, L. J.; Weckstein, D. J.; Patnaik, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Association of machine learning (ML)-derived histological features with transcriptomic molecular subtypes in advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Beig, N.; Nofallah, S.; McDermott, D. F.; Motzer, R. J.; Powles, T.; Rini, B. I.; Koeppen, H.; Banchereau, R.; Markey, M.; Finberg, I.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 ((225)Ac) -labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Morris, M. J.; Wong, J. Y. C.; Nordquist, L.; Szmulewitz, R. Z.; Agarwal, N.; Attiyeh, E. F.; Max, S. I.; Divgi, C. R.; Patricia, D.; Cao, Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance)
    Meeting Abstract

    Halabi, S.; Luo, B.; Guo, S. S.; Knutson, T.; Lyman, J.; Kobilka, A.; Beltran, H.; Antonarakis, E. S.; Rosenberg, J. E.; Galsky, M. D.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 2 trial of ADT interruption in patients responding exceptionally to AR-pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM/Alliance A032101)
    Meeting Abstract

    Choudhury, A. D.; Heller, G.; Reimers, M. A.; Laccetti, A. L.; Smieliauskas, F.; Ravi, P.; Dooley, K.; Mazza, G. L.; Gartrell, B. A.; Steen, P. D.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save